Preclinical evaluation of novel anti-diabetic agents requires translatable models that accurately recapitulate the distinct pathophysiologies of hyperglycemia and insulin resistance. BioLegacy utilizes a comprehensive, multi-species platform of well-characterized Type 1 and Type 2 diabetes models. Integrating these gold-standard genetic and induced models with pivotal functional tests of glucose homeostasis, we deliver clear, quantitative data on glycemic control and insulin sensitivity essential for advancing your diabetes therapeutic.
BioLegacy’s evaluation of anti-obesity therapeutics extend beyond simple body weight measurement to nuanced characterizations of their effect on body composition and energy expenditure. We use both diet-induced and genetic models of obesity to provide these holistic assessments. Integrating gold-standard in vivo systems with precise, quantitative bioanalytical readouts, we deliver a clear, mechanistic profile of your compound’s ability to reduce adiposity, preserve lean mass, and favorably alter metabolic parameters.
